185
Participants
Start Date
March 31, 2011
Primary Completion Date
March 31, 2016
Study Completion Date
March 31, 2016
Onartuzumab
Onartuzumab will be administered as intravenous (IV) infusion at a dose of 10 milligrams per kilogram (mg/kg) on Day 1 and Day 15 of each 28-day cycle. The dose of onartuzumab will be based on the participant's weight at screening and will remain the same throughout the study.
Bevacizumab
Bevacizumab will be administered as IV infusion at a dose of 10 mg/kg on Day 1 and Day 15 of each 28-day cycle. The dose of bevacizumab will be based on the participant's weight at screening and will remain the same throughout the study.
Paclitaxel
Paclitaxel will be administered as IV infusion at a dose of 90 milligrams per meter-squared (mg/m\^2) on Day 1, Day 8, and Day 15 of each 28-day cycle.
Bevacizumab Placebo
Placebo matching to bevacizumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
Onartuzumab Placebo
Placebo matching to onartuzumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
Institut Jules Bordet, Brussels
Sint Augustinus Wilrijk, Wilrijk
UZ Antwerpen, Edegem
Jessa Zkh (Campus Virga Jesse), Hasselt
CHU Sart-Tilman, Liège
CH Jolimont - Lobbes (Jolimont), Haine-Saint-Paul
AZ Sint Lucas (Sint Lucas), Ghent
Hospital Universitario Puerta del Mar; Servicio de Oncologia, Cadiz
North Shore Hem Onc Associates, East Setauket
Centre Francois Baclesse; Gastro-Enterologie, Caen
Centro Oncológico Gallego José Antonio Quiroga y Piñeiro, Servicio de Oncologia, A Coruña
Magee Womens Hospital, Pittsburgh
Centre Georges Francois Leclerc; Oncologie 3, Dijon
Duke University Medical Center, Durham
Hospital Universitario Puerta de Hierro, Majadahonda
South Carolina Onc. Associate, Columbia
Charleston Hematology Oncology, Charleston
Suburban Hematology Oncology, Lawrenceville
Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse
Institut Bergonie; Oncologie, Bordeaux
Holy Cross Hospital, Fort Lauderdale
Florida Cancer Specialists; SCRI, Fort Myers
Institut régional du Cancer Montpellier, Montpellier
The Sarah Cannon Research Inst, Nashville
SCRI Tennessee Oncology Chattanooga, Chattanooga
Ico Rene Gauducheau; Oncologie, Saint-Herblain
Karmanos Cancer Institute.., Detroit
Klinik Johann Wolfgang von Goethe Uni, Frankfurt am Main
Praxis Dr. med. Klausmann; SHOD, Aschaffenburg
Centre Leon Berard, Lyon
Universitätsklinik Tübingen; Frauenklinik, Tübingen
Institut Curie; Oncologie Medicale, Paris
MD Anderson Cancer Center, Houston
Klinikum rechts der Isar der TU München; Frauenklinik, München
Northern Utah Associates, Ogden
Comprehensive Cancer Centers of Nevada, Las Vegas
Univ of California Los Angeles, Los Angeles
Sharp Healthcare; Oncology Research Program, San Diego
Centre Rene Huguenin; CONSULT SPECIALISEES, Saint-Cloud
St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr, Fullerton
Comprehensive Blood/Cancer Ctr, Bakersfield
Kaiser Permanente - Vallejo, Vallejo
Kaiser Permanente Sacramento Medical Center, Sacramento
Can Care Assoc Med Group Inc; Beach Cities Offices, Los Angeles
Cancer Center of Kansas, Wichita
Massachusetts General Hospital, Boston
Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona
Instituto Catalán de Oncología; Servicio de Farmacia, Barcelona
Brighton and Sussex Univ Hosp, Brighton
Christie Hospital NHS Trust, Manchester
The Clatterbridge Cancer Ctr For Oncolgy, Metropolitan Borough of Wirral
Mount Vernon Hospital; Centre For Cancer Treatment, Northwood
Nottingham City Hospital; Oncology, Nottingham
Lead Sponsor
Hoffmann-La Roche
INDUSTRY
Genentech, Inc.
INDUSTRY